The main advantages of SGLT2 inhibitors usage in older frail patients are driven by a reduction in cardio-renal events (reduced CV mortality, HHF and renal adverse events) and improved HF-related health status [14, 16, 22, 72–74] rather than its glycaemic benefits. This evidence concerns the gene SLC5A2 and hydrops fetalis.